CD8A and neoplasm: The delivery of a transforming growth factor‐beta receptor 1 (TGFβR1) inhibitor (SD208) that obstructed TGFβ signaling mediated immunosuppression, enabled restoring the function of effector CD8+ T cells against MC38 tumor, while free drugs showed limited therapeutic effect.